Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Income towards Parent Company (2020 - 2025)

Historic Income towards Parent Company for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$35.7 million.

  • TScan Therapeutics' Income towards Parent Company fell 1948.34% to -$35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.5 million, marking a year-over-year decrease of 2713.76%. This contributed to the annual value of -$126.4 million for FY2024, which is 4168.55% down from last year.
  • TScan Therapeutics' Income towards Parent Company amounted to -$35.7 million in Q3 2025, which was down 1948.34% from -$37.0 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Income towards Parent Company high stood at -$7.9 million for Q1 2021, and its period low was -$37.0 million during Q2 2025.
  • In the last 5 years, TScan Therapeutics' Income towards Parent Company had a median value of -$22.6 million in 2023 and averaged -$23.0 million.
  • In the last 5 years, TScan Therapeutics' Income towards Parent Company plummeted by 12090.66% in 2021 and then plummeted by 256.33% in 2022.
  • TScan Therapeutics' Income towards Parent Company (Quarter) stood at -$14.2 million in 2021, then tumbled by 31.85% to -$18.7 million in 2022, then dropped by 4.75% to -$19.6 million in 2023, then tumbled by 77.02% to -$34.7 million in 2024, then fell by 2.85% to -$35.7 million in 2025.
  • Its Income towards Parent Company was -$35.7 million in Q3 2025, compared to -$37.0 million in Q2 2025 and -$34.1 million in Q1 2025.